Current and historical daily PE Ratio for Algorae Pharmaceuticals Ltd (
) from 2004 to Jun 08 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Algorae Pharmaceuticals stock (ASX:1AI) PE ratio as of Jun 08 2024 is 0.
More Details
Algorae Pharmaceuticals Ltd (ASX:1AI) PE Ratio (TTM) Chart
Algorae Pharmaceuticals Ltd (ASX:1AI) PE Ratio (TTM) Historical Data
View and export this data going back to 2004. Start your Free Trial
Total 1286
- 1
- 2
- 3
- 4
- 5
- 6
- 15
| Algorae Pharmaceuticals PE Ratio (TTM) Historical Data | |||
|---|---|---|---|
| Date | PE Ratio (TTM) Data | Date | PE Ratio (TTM) Data |
| 2024-06-09 | At Loss | 2024-04-08 | At Loss |
| 2024-06-07 | At Loss | 2024-04-05 | At Loss |
| 2024-06-06 | At Loss | 2024-04-04 | At Loss |
| 2024-06-05 | At Loss | 2024-04-03 | At Loss |
| 2024-06-04 | At Loss | 2024-04-02 | At Loss |
| 2024-06-03 | At Loss | 2024-04-01 | At Loss |
| 2024-05-31 | At Loss | 2024-03-29 | At Loss |
| 2024-05-30 | At Loss | 2024-03-28 | At Loss |
| 2024-05-29 | At Loss | 2024-03-27 | At Loss |
| 2024-05-28 | At Loss | 2024-03-26 | At Loss |
| 2024-05-27 | At Loss | 2024-03-25 | At Loss |
| 2024-05-24 | At Loss | 2024-03-22 | At Loss |
| 2024-05-23 | At Loss | 2024-03-21 | At Loss |
| 2024-05-22 | At Loss | 2024-03-20 | At Loss |
| 2024-05-21 | At Loss | 2024-03-19 | At Loss |
| 2024-05-20 | At Loss | 2024-03-18 | At Loss |
| 2024-05-17 | At Loss | 2024-03-15 | At Loss |
| 2024-05-16 | At Loss | 2024-03-14 | At Loss |
| 2024-05-15 | At Loss | 2024-03-13 | At Loss |
| 2024-05-14 | At Loss | 2024-03-12 | At Loss |
| 2024-05-13 | At Loss | 2024-03-11 | At Loss |
| 2024-05-10 | At Loss | 2024-03-08 | At Loss |
| 2024-05-09 | At Loss | 2024-03-07 | At Loss |
| 2024-05-08 | At Loss | 2024-03-06 | At Loss |
| 2024-05-07 | At Loss | 2024-03-05 | At Loss |
| 2024-05-06 | At Loss | 2024-03-04 | At Loss |
| 2024-05-03 | At Loss | 2024-03-01 | At Loss |
| 2024-05-02 | At Loss | 2024-02-29 | At Loss |
| 2024-05-01 | At Loss | 2024-02-28 | At Loss |
| 2024-04-30 | At Loss | 2024-02-27 | At Loss |
| 2024-04-29 | At Loss | 2024-02-26 | At Loss |
| 2024-04-26 | At Loss | 2024-02-23 | At Loss |
| 2024-04-25 | At Loss | 2024-02-22 | At Loss |
| 2024-04-24 | At Loss | 2024-02-21 | At Loss |
| 2024-04-23 | At Loss | 2024-02-20 | At Loss |
| 2024-04-22 | At Loss | 2024-02-19 | At Loss |
| 2024-04-19 | At Loss | 2024-02-16 | At Loss |
| 2024-04-18 | At Loss | 2024-02-15 | At Loss |
| 2024-04-17 | At Loss | 2024-02-14 | At Loss |
| 2024-04-16 | At Loss | 2024-02-13 | At Loss |
| 2024-04-15 | At Loss | 2024-02-12 | At Loss |
| 2024-04-12 | At Loss | 2024-02-09 | At Loss |
| 2024-04-11 | At Loss | 2024-02-08 | At Loss |
| 2024-04-10 | At Loss | 2024-02-07 | At Loss |
| 2024-04-09 | At Loss | 2024-02-06 | At Loss |
Algorae Pharmaceuticals Ltd (ASX:1AI) PE Ratio (TTM) Comparison
| Company | Market Cap(Mil) | PE Ratio (TTM) |
|---|
Business Description
Business Description
Algorae Pharmaceuticals Ltd
ISIN : AU0000296022
Compare
Compare
Traded in other countries / regions
1AI.AustraliaLHI0.GermanyLVCLF.USA IPO Date
2004-09-01Description
Algorae Pharmaceuticals Ltd is a clinical-stage pharmaceutical company developing transformative solutions for undermet medical needs in the community. The firm develops AlgoraeOS, a closed-loop platform, leveraging computational tools to generate novel insights in silico that are being developed to initiate or accelerate therapeutic programs. Its lead products comprise AI-116, a novel combination drug candidate of cannabidiol (CBD) and an off-patent pharmaceutical ingredient. It is conceptualised to be a potential treatment for dementia, including Alzheimer's disease; NTCELL is an alginate-coated capsule containing clusters of neonatal porcine choroid plexus cells. It also offers LP-003 Anti-obesity Drug and LC-002 migraine treatment.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers